RenovoRx Receives First Japanese Notice Of Allowance For Patent Protecting Its RenovoCath® Device For Targeted Drug Delivery Through The Vasa Vasorum

RenovoRx, Inc., a life-sciences company developing targeted oncology therapies and commercializing its FDA-cleared RenovoCath drug-delivery device, announced that the Japan Patent Office has issued a Notice of Allowance for the company’s first Japanese patent application (JP 2024-559262), titled “Method and Apparatus for Delivering an Agent Through the Vasa Vasorum.”

This newly allowed patent strengthens RenovoRx’s global intellectual property portfolio and further supports its approach to targeted drug delivery. It also provides important protection for the company’s therapeutic platform in Japan, a strategically significant market.

The approved claims cover the RenovoCath dual-occlusion, catheter-based system, which includes integrated imaging and pressure-sensing features designed to deliver drugs or biologics directly into targeted tissue via the vasa vasorum. These microscopic vessels supply the walls of major arteries and offer a pathway to reach tissue surrounding the blood vessels. Delivering therapy at such a precise, local level is a defining characteristic of the RenovoCath system and enables targeted treatment without the widespread side effects associated with systemic options like intravenous chemotherapy.

Shaun Bagai, Chief Executive Officer of RenovoRx, stated that the patent marks a meaningful milestone in the company’s effort to expand its international intellectual property. He noted that leveraging the vasa vasorum as a route for localized drug delivery represents a significant advancement in treating difficult-to-reach tumors. According to Bagai, delivering therapeutic agents closer to the tumor may help improve patient outcomes while reducing systemic exposure.

Bagai also emphasized that the patent highlights the importance of the company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) platform, which aims to address limitations seen in both conventional systemic therapies and existing local treatment methods.

As RenovoRx continues to commercialize RenovoCath in the United States, the addition of this Japanese patent strengthens the company’s long-term commercial strategy. It supports potential future partnerships, licensing discussions, and expansion efforts in Japan.

With this latest allowance, RenovoRx now holds 19 issued and allowed patents worldwide and has 14 additional pending patents related to its TAMP platform and the RenovoCath device, further reinforcing its commitment to protecting and advancing its drug-delivery innovations.